STEM³ Platform Validation & Target Discovery
Matrix-rich solid tumors (e.g., Sarcoma)
Key Facts
About SyzOnc
SyzOnc is a private, pre-clinical biotech tackling the significant unmet need in treating matrix-rich solid tumors with poor survival rates, such as sarcoma, pancreatic, and liver cancers. The company has developed the STEM³ (System for Tumor Ecosystem Modulation) platform, an integrated AI-driven system designed to overcome the limitations of reductionist approaches by modeling the complex tumor microenvironment to discover novel therapeutic targets and compounds. Founded by a team of cancer biologists and AI experts from leading institutions, the company has garnered recognition through awards like the MIT Royalty Pharma Faculty Founder Competition Grand Prize. SyzOnc is currently in the platform validation and early drug discovery stage, with no disclosed clinical pipeline.
View full company profile